Skip to main content
Caplight Logo









Inicure AB

Inicure AB

Private
GöteborgHealthcare & Life Scienceshttps://inicure.com/

Last Round

Grant

Jun 3, 2026

Total Funding Raised

$40,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Inicure AB is a biotechnology company that develops small-molecule formyl peptide receptor-1 (FPR1) agonists to treat infectious diseases and combat antibiotic resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antimicrobial resistanceAMRFPR1 agonistshost-directed therapyinnate immune systemdrug discoveryanti-infectivesmall-molecule drugssuperbug treatmentbiotech startuppreclinical developmentimmunotherapydrug-resistant bacteriapharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inicure AB Comparables

Compare Inicure AB with similar companies based on industry and business-model similarity.

Inicure AB comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
smartbax GmbH
84%
Disperazol Pharma ApS
82%
APY Therapeutics
79%

Inicure AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 3, 2026
GrantFeb 13, 2026
AcceleratorJun 1, 2024

Inicure AB Investors

Notable investors and investment history

Inicure AB investors
InvestorRounds
Vasa Angels IAccelerator
INCATEGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 3, 2026

    Secured $30K in grant funding.

  • Feb 13, 2026

    $10K grant received.

Inicure AB Filings

Explore SEC and related filing metadata, where available.

Inicure AB filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Inicure AB's valuation, stock price, and market status.

Is Inicure AB a public or private company?

Inicure AB is a private company.

What is the current stock price of Inicure AB?

Inicure AB is a private company with no public stock price. Caplight tracks Inicure AB's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Inicure AB worth (valuation)?

Valuation information for Inicure AB is not publicly available.

Can I buy Inicure AB stock?

Inicure AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Inicure AB's last funding round?

Inicure AB's most recent funding round was Grant on June 3, 2026.

Who are the main investors in Inicure AB?

Key investors in Inicure AB include Vasa Angels I.

Will Inicure AB IPO soon?

No public IPO plans have been announced for Inicure AB.

How can I track Inicure AB secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Inicure AB's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGöteborg
Employee Range3
Year Founded2024
Last FundingJun 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?